Nuclear factor-kappa B as a resistance factor to platinum-based antineoplasic drugs

Metal-Based Drugs

Volumn 2008, Issue , 2008, Pages

  Lagunas, Vilma Maldonado ^a   Meléndez Zajgla, Jorge ^b  

^a Instituto Nacional de Cancerológica   (Mexico)

^b INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPLATIN; MITOPODOZIDE; OXALIPLATIN; PLATINUM; SATRAPLATIN;

ANTINEOPLASTIC ACTIVITY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 43849109184     PISSN: 07930291     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/576104     Document Type: Review

References (57)

1. Peyrone M., Ueber die einwirkung des ammoniaks auf platinchlorür Annalen der Chemie und Pharmacie 1844 51 1 1 29
2. Werner A., Beitrag zur konstitution anorganischer verbindungen Zeitschrift für anorganische Chemie 1893 3 1 267 330
3. Rosenberg B., Van Camp L., Krigas T., Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode Nature 1965 205 4972 698 699
4. Rosenberg B., Platinum coordination complexes in cancer chemotherapy Naturwissenschaften 1973 60 9 399 406
5. Ishida S., Lee J., Thiele D. J., Herskowitz I., Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals Proceedings of the National Academy of Sciences of the United States of America 2002 99 22 14298 14302
6. Kuo M. T., Chen H. H. W., Song I.-S., Savaraj N., Ishikawa T., The roles of copper transporters in cisplatin resistance Cancer and Metastasis Reviews 2007 26 1 71 83
7. Laurent G., Erickson L. C., Sharkey N. A., Kohn K. W., DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum(II) in human normal and tumor cell lines Cancer Research 1981 41 3347 3351
8. Chválová K., Brabec V., Kašpárková J., Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin Nucleic Acids Research 2007 35 6 1812 1821
9. Martelli L., Di Mario F., Botti P., Ragazzi E., Martelli M., Kelland L., Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status Biochemical Pharmacology 2007 74 1 20 27
10. Brabec V., Kasparkova J., Modifications of DNA by platinum complexes relation to resistance of tumors to platinum antitumor drugs Drug Resistance Updates 2005 8 3 131 146
11. Husain I., Chaney S. G., Sancar A., Repair of cis-platinum-DNA adducts by ABC excinuclease in vivo and in vitro Journal of Bacteriology 1985 163 3 817 823
12. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K. H., Pommier Y., Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells Cancer Research 2002 62 17 4899 4902
13. Maldonado V., Melendez J., Gonzalez H., Ortega A., Internucleosomal DNA cleavage in HeLa cells exposed to cisplatin Biochemistry and Molecular Biology International 1995 37 4 691 696
14. Kim Y. K., Kim H. J., Kwon C. H., Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells Journal of Applied Toxicology 2005 25 5 374 382
15. Zanke B. W., Boudreau K., Rubie E., The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat Current Biology 1996 6 5 606 613
16. Sánchez-Pérez I., Martínez-Gomariz M., Williams D., Keyse S. M., Perona R., CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin Oncogene 2000 19 45 5142 5152
17. Bragado P., Armesilla A., Silva A., Porras A., Apoptosis by cisplatin requires p53 mediated p38 α MAPK activation through ROS generation Apoptosis 2007 12 9 1733 1742
18. Pandey P., Raingeaud J., Kaneki M., Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms Journal of Biological Chemistry 1996 271 39 23775 23779
19. Mitsuuchi Y., Johnson S. W., Selvakumaran M., Williams S. J., Hamilton T. C., Testa J. R., The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel Cancer Research 2000 60 19 5390 5394
20. Wang D., Lippard S. J., Cellular processing of platinum anticancer drugs Nature Reviews Drug Discovery 2005 4 4 307 320
21. Mabuchi S., Ohmichi M., Nishio Y., Inhibition of NF- κ B increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models Journal of Biological Chemistry 2004 279 22 23477 23485
22. Maldonado V., Meléndez-Zajgla J., Ortega A., Modulation of NF- κ B, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1997 381 1 67 75
23. Hoffmann A., Natoli G., Ghosh G., Transcriptional regulation via the NF- κ B signaling module Oncogene 2006 25 51 6706 6716
24. Burstein E., Duckett C. S., Dying for NF- κ B? Control of cell death by transcriptional regulation of the apoptotic machinery Current Opinion in Cell Biology 2003 15 6 732 737
25. Marienfeld R. B., Palkowitsch L., Ghosh S., Dimerization of the I κ B kinase-binding domain of NEMO is required for tumor necrosis factor alpha-induced NF- κ B activity Molecular and Cellular Biology 2006 26 24 9209 9219
26. Barry M. A., Behnke C. A., Eastman A., Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia Biochemical Pharmacology 1990 40 10 2353 2362
27. Sodhi A., Singh R. A. K., Mechanism of NF- κ B translocation in macrophages treated in vitro with cisplatin Immunology Letters 1998 63 1 9 17
28. Eichholtz-Wirth H., Sagan D., I κ B/NF- κ B mediated cisplatin resistance in HeLa cells after low-dose γ -irradiation is associated with altered SODD expression Apoptosis 2000 5 3 255 263
29. Chuang S.-E., Yeh P.-Y., Lu Y.-S., Basal levels and patterns of anticancer drug-induced activation of nuclear factor- κ B (NF- κ B), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells Biochemical Pharmacology 2002 63 9 1709 1716
30. Francescato H. D. C., Costa R. S., Scavone C., Coimbra T. M., Parthenolide reduces cisplatin-induced renal damage Toxicology 2007 230 1 64 75
31. Kim J. S., Lee J. M., Chwae Y.-J., Cisplatin-induced apoptosis in Hep3B cells: mitochondria-dependent and -independent pathways Biochemical Pharmacology 2004 67 8 1459 1468
32. Beg A. A., Sha W. C., Bronson R. T., Ghosh S., Baltimore D., Embryonic lethality and liver degeneration in mice lacking the RelA component of NF- κ B Nature 1995 376 6536 167 170
33. Chiao P. J., Miyamoto S., Verma I. M., Autoregulation of I κ B α activity Proceedings of the National Academy of Sciences of the United States of America 1994 91 1 28 32
34. Kato T., Duffey D. C., Ondrey F. G., Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF- κ B Head & Neck 2000 22 8 748 759
35. O'Brien M. E., Anderson H., Kaukel E., SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results Annals of Oncology 2004 15 6 906 914
36. Ruan H.-Y., Masuda M., Ito A., Effects of a novel NF- κ B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines Head & Neck 2006 28 2 158 165
37. Tozawa K., Okamoto T., Hayashi Y., Sasaki S., Kawai N., Kohri K., N-acetyl-L-cysteine enhances chemotherapeutic effect on prostate cancer cells Urological Research 2002 30 1 53 58
38. Abdel-Latif M. M. M., Raouf A. A., Sabra K., Kelleher D., Reynolds J. V., Vitamin C enhances chemosensitization of esophageal cancer cells in vitro Journal of Chemotherapy 2005 17 5 539 549
39. Abdel-Latif M. M. M., O'Riordan J. M., Ravi N., Kelleher D., Reynolds J. V., Activated nuclear factor- κ B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy Diseases of the Esophagus 2005 18 4 246 252
40. Yeh P. Y., Chuang S.-E., Yeh K.-H., Song Y. C., Cheng A.-L., Involvement of nuclear transcription factor- κ B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells Biochemical Pharmacology 2003 66 1 25 33
41. Eichholtz-Wirth H., Marx K., Clonal variability of radiation-induced cisplatin resistant HeLa cells Anticancer Research 1998 18 2989 2991
42. Aghajanian C., Clinical update: novel targets in gynecologic malignancies Seminars in Oncology 2004 31 16 22 26
43. Lee C. T., Seol J. Y., Lee S. Y., The effect of adenovirus-I κ B α transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diamminedichloroplatinum(II)(cisplatin) and doxorubicin(adriamycin) Lung Cancer 2003 41 2 199 206
44. Sánchez-Pérez I., Perona R., Lack of c-Jun activity increases survival to cisplatin FEBS Letters 1999 453 1-2 151 158
45. Sánchez-Pérez I., Benitah S. A., Martínez-Gomariz M., Lacal J. C., Perona R., Cell stress and MEKK1-mediated c-Jun activation modulate NF κ B activity and cell viability Molecular Biology of the Cell 2002 13 8 2933 2945
46. Yeh P. Y., Yeh K.-H., Chuang S.-E., Song Y. C., Cheng A.-L., Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF- κ B activation by protein phosphatase 4-mediated NF- κ B p65 Thr dephosphorylation Journal of Biological Chemistry 2004 279 25 26143 26148
47. Pahl H. L., Activators and target genes of Rel/NF- κ B transcription factors Oncogene 1999 18 49 6853 6866
48. Kim J. K., Kim K. D., Lee E., Up-regulation of Bfl-1/A1 via NF- κ B activation in cisplatin-resistant human bladder cancer cell line Cancer Letters 2004 212 1 61 70
49. Park J. K., Chung Y. M., Kang S., c-Myc exerts a protective function through ornithine decarboxylase against cellular insults Molecular Pharmacology 2002 62 6 1400 1408
50. Lokich J., Anderson N., Carboplatin versus cisplatin in solid tumors: an analysis of the literature Annals of Oncology 1998 9 1 13 21
51. Singh S., Bhat M. K., Carboplatin induces apoptotic cell death through downregulation of constitutively active nuclear factor- κ B in human HPV-18 E6-positive HEp-2 cells Biochemical and Biophysical Research Communications 2004 318 2 346 353
52. Weaver K. D., Yeyeodu S., Cusack J. C. Jr., Baldwin A. S. Jr., Ewend M. G., Potentiation of chemotherapeutic agents following antagonism of nuclear factor κ B in human gliomas Journal of Neuro-Oncology 2003 61 3 187 196
53. Raymond E., Faivre S., Chaney S., Woynarowski J., Cvitkovic E., Cellular and molecular pharmacology of oxaliplatin Molecular Cancer Therapeutics 2002 1 3 227 235
54. Rakitina T. V., Vasilevskaya I. A., O'Dwyer P. J., Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor κ B signaling Cancer Research 2003 63 24 8600 8605
55. Fokkema E., Groen H. J. M., Helder M. N., de Vries E. G. E., Meijer C., JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin Biochemical Pharmacology 2002 63 11 1989 1996
56. Meerum Terwogt J. M., Groenewegen G., Pluim D., Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin Cancer Chemotherapy and Pharmacology 2002 49 3 201 210
57. Stathopoulos G. P., Boulikas T., Vougiouka M., Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study Oncology Reports 2005 13 4 589 595